Acute Myeloid Leukemia | Bringing the Patient into the Equation: A Pilot CME Initiative on the Treatment of Acute Myeloid Leukemia — Issue 2

published 1 month ago by Dr Neil Love

Featuring Dr Courtney D DiNardo’s perspectives on her time spent speaking with patients with acute myeloid leukemia from the practices of community oncologists Drs KS Kumar and Andrew C Rettew, including the following topics: Case: A woman in her early 70s with acute myeloid leukemia (AML) and an IDH mutation receives venetoclax and azacytidine (0:00) Selection of patients for treatment with venetoclax/azacitidine versus intensive 7 + 3 chemotherapy; optimal application of venetoclax/azacytidine (5:41) Tolerability and side effects of venetoclax/azacitidine; testing for IDH mutations and choice of therapy for patients with AML and an IDH mutation (14:24) Duration of therapy and long-term outcomes with venetoclax/azacitidine; clinical research on combination therapy with venetoclax and oral hypomethylating agents (HMAs) (23:08) Treatment options for patients with AML who experience disease progression on venetoclax/azacitidine; use of IDH inhibitors for AML (29:23) Case: A woman in her mid-50s with a complex medical history is diagnosed with AML and receives 7 + 3 chemotherapy and gemtuzumab ozogamicin (34:24) Case: A man in his early 70s with AML and a FLT3-ITD mutation receives 7 + 3 chemotherapy and midostaurin (47:36) Optimal approach to the management of AML with FLT3 mutations (51:20) Impact of COVID-19 on the clinical care of patients with AML (57:37) Case: A man in his early 70s with AML with myelodysplasia-related changes and mutations in RUNX1, SRSF2, ASXL1 and IDH2 receives liposomal daunorubicin and cytarabine (CPX-351) followed by enasidenib (1:07:10) Activity and tolerability of CPX-351 for AML; patient selection (1:11:19) Choice between a venetoclax/HMA combination and an IDH inhibitor for patients with progressive AML and an IDH mutation (1:17:53) Feasibility and efficacy of stem cell transplantation in patients with relapsed AML; use and tolerability of glasdegib and low-dose cytarabine for AML (1:25:52) CME information and select publications

more episodes from Research To Practice | Oncology Videos